CIS BIOPHARMA Market Research Report

Background

Company Overview

CIS BIOPHARMA is a biotechnology company headquartered in Basel, Switzerland, dedicated to revolutionizing cancer treatment through novel targeted therapies. Established in 1952, the company has evolved from its origins in chemistry and surfactant production to focus on developing innovative oncology treatments. Its mission is to help cancer patients live longer and better lives by pioneering precision cancer therapies that selectively target tumor cells.

Mission and Vision

• Mission: Unleashing the power of targeted therapies to improve patient outcomes in oncology.

• Vision: To help cancer patients live longer and better lives through innovative cancer therapies.

Primary Area of Focus

CIS BIOPHARMA specializes in developing next-generation antibody-drug conjugates (ADCs) and radioligand therapies aimed at treating aggressive cancers with high unmet medical needs, such as small cell lung cancer (SCLC), glioblastoma multiforme (GBM), and brain metastases.

Industry Significance

Operating within the biotechnology sector, CIS BIOPHARMA contributes to the advancement of precision oncology by developing therapies that specifically target tumor cells, thereby minimizing damage to healthy tissues and improving patient quality of life.

Key Strategic Focus

Core Objectives

• Develop innovative cancer therapies targeting aggressive tumors with high unmet needs.

• Advance the clinical development of proprietary ADCs and radioligand therapies.

• Establish strategic partnerships to enhance research capabilities and expedite product development.

Specific Areas of Specialization

• Antibody-Drug Conjugates (ADCs):

• CBO-001 targeting small cell lung cancer (SCLC).

• CBO-002 targeting brain metastases (BM).

• Radioligand Therapies (RLTs):

• Development of novel radioligands for targeted cancer treatment.

Key Technologies Utilized

• Bioconjugation platforms for ADC development.

• Protein engineering techniques for optimizing therapeutic efficacy.

• Radiopharmaceutical chemistry for RLT development.

Primary Markets or Conditions Targeted

• Oncology, with a focus on aggressive cancers such as SCLC, GBM, and brain metastases.

Financials and Funding

Funding History

Specific details regarding CIS BIOPHARMA's total funds raised and recent funding rounds are not publicly disclosed. The company has been privately held since its inception and has not reported any public funding events.

Notable Investors

Information about individual investors or venture capital firms involved with CIS BIOPHARMA is not publicly available.

Intended Utilization of Capital

While specific allocations are not detailed, it is reasonable to infer that any capital raised would be directed towards:

• Advancing the clinical development of pipeline candidates.

• Enhancing research and development capabilities.

• Expanding operational infrastructure to support growth.

Pipeline Development

Key Pipeline Candidates

• CBO-001: An advanced ADC targeting CD171 (L1 surface molecule) for the treatment of SCLC.

• CBO-002: An ADC engineered to overcome limitations in treating brain metastases, particularly those associated with lung and breast cancers.

Stages of Clinical Trials or Product Development

• Both CBO-001 and CBO-002 are in preclinical stages, with plans for clinical trials pending regulatory approvals.

Target Conditions

• CBO-001: Small cell lung cancer (SCLC).

• CBO-002: Brain metastases (BM).

Relevant Timelines for Anticipated Milestones

• Specific timelines for clinical trial initiation and subsequent milestones have not been publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

• Advanced bioconjugation methods for ADC development.

• Innovative linker technologies to enhance drug stability and efficacy.

• Radiopharmaceutical chemistry for the development of targeted radioligand therapies.

Significant Scientific Methods

• Protein engineering for optimizing antibody specificity and affinity.

• Radiolabeling techniques for imaging and therapeutic applications.

Leadership Team

Executive Profiles

• Christoph Schäfer, MBA: Co-founder and CEO with over 25 years of experience in the life sciences industry, including roles at Novartis, Alcon, and CIS Pharma. He focuses on developing innovative cancer therapies at CIS BIOPHARMA.

• Kathrin Locher, PhD: Co-founder and Board Member with expertise in non-clinical safety and toxicology, having worked at Roche, Novartis, and Amgen. She applies her knowledge to support early development of drug candidates.

• Anders Härfstrand, MD, PhD: Board Member with 36 years in the pharmaceutical industry, specializing in commercial operations and product development, with experience at Pfizer and Serono.

• Andrea Buscaglia, MBA: Chief Financial Officer with 24 years in corporate finance within the life sciences sector, having held senior positions at Serono, Nitec Pharma, and Endosense.

• Ruggero Della Bitta, MD, PhD: Chief Medical Officer with over 30 years in clinical oncology, including roles at Roche-Genentech and Merck-Serono.

• Dominik Brücher, PhD: Chief Technology Officer with expertise in protein engineering and biologics, having contributed to drug development projects at Roche Pharmaceutical.

• Michael Hackebeil, MSc: